SoniVie Receives IDE Approval from FDA for Its Pilot Study to Treat Hypertension with Its Renal Artery Denervation TIVUS™ Technology

SoniVie announced that the US FDA granted IDE approval for its “REDUCED1” Pilot study to treat resistant hypertension patients with renal artery denervation using TIVUS, its innovative ultra-sound ablation system.
[SoniVie (Cision US, Inc.)]
Press Release

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News